Short communicationInterleukin-1 contributes to the induction of nitric oxide synthase by endotoxin in vivo
References (16)
- et al.
Induction of nitric oxide by cytokines in vascular smooth muscle cells
FEBS Lett.
(1990) - et al.
Blocking interleukin-1: interleukin-1 receptor antagonist in vivo and in vitro
Immunol. Today
(1991) - et al.
Synergism between interleukin-1 beta and interferon-gamma, an inducer of nitric oxide synthase, in rat lung fibroblasts
Eur. J. Pharmacol.
(1992) - et al.
Dexamethasone prevents the induction by endotoxin of a nitric oxide synthase and the associated effects on vascular tone: and insight into endotoxin shock
Biochem. Biophys. Res. Commun.
(1990) - et al.
Widespread tissue distribution, species distribution and changes in activity of calcium-dependent and calcium-independent nitric oxide synthases
FEBS Lett.
(1991) - et al.
Inhibition of nitric oxide synthesis reduces the hypotension induced by bacterial lipopolysaccharides in the rat in vivo
Eur. J. Pharmacol.
(1990) - et al.
Interleukin-1 induces prolonged L-arginine-dependent cyclic guanosine monophosphate and nitrite production in rat vascular smooth muscle cells
J. Clin. Invest.
(1991) The cytokine network in the critically ill
Anaesth. Intensive Care
(1992)
Cited by (85)
CAT-1 as a novel CAM stabilizes endothelial integrity and mediates the protective actions of l-Arg via a NO-independent mechanism
2015, Journal of Molecular and Cellular CardiologyCitation Excerpt :The excessive NO production by iNOS in this case results in relaxation of vascular smooth muscle through raising intracellular cyclic guanosine monophosphate (cGMP) levels and then causes hypotension and vascular hyporeactivity [58]. However, NOS inhibitors were not uniformly successful in improving sepsis-induced hypotension, and inhibition of NOS only partially restores the endotoxin-induced vascular hyporeactivity [59–62]. Furthermore, based on other recent understanding of contributing factors and mechanisms of uncoupling of eNOS and increased eNOS-derived production of ROS and H2O2, the innovative therapies targeting at these mechanisms of action, such as BH4 has been repeatedly found, have failed in clinical trials despite early success in pre-clinical models [63].
Vasoplegia in septic shock: Do we really fight the right enemy?
2014, Journal of Critical CareCitation Excerpt :Nitric oxide (NO) induced by a Ca2 +-independent isoform of NO synthase (iNOS) has been suggested to play an important role in activating soluble guanylyl cyclase (sGC), thus producing relaxation of vascular smooth muscle through rising in intracellular cyclic guanosine monophosphate (cGMP) levels and then causes hypotension and vascular hyporeactivity [9,10]. However, NO synthase (NOS) inhibitors were not uniformly successful in improving sepsis-induced hypotension outcome, and inhibition of NOS only partially restores the endotoxin-induced vascular hyporeactivity [11-14]. The aim of the present review is to discuss the most recent cited underlying mechanisms of decreased responsiveness to vasoconstrictors in sepsis and to briefly outline current therapeutic strategies and possible future approaches.
Protective effect of Arbutus unedo aqueous extract in carrageenan-induced lung inflammation in mice
2008, Pharmacological ResearchNitric oxide in septic shock
1999, Biochimica et Biophysica Acta - BioenergeticsAn agonist of adenosine A<inf>3</inf> receptors decreases interleukin-12 and interferon-γ production and prevents lethality in endotoxemic mice
1998, European Journal of Pharmacology